Search Results - Kausik K. Ray

Refine Results
  1. 1
    Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries

    Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibi... by Toshiyuki Nishikido, Toshiyuki Nishikido, Kausik K. Ray

    Published 2019-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Dietary food patterns and glucose/insulin homeostasis: a cross-sectional study involving 24,182 adult Americans

    Dietary food patterns and glucose/insulin homeostasis: a cross-sectional study involving 24,182 adult Americans by Mohsen Mazidi, Andre Pascal Kengne, Dimitri P. Mikhailidis, Peter P. Toth, Kausik K. Ray, Maciej Banach

    Published 2017-10-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Factors Associated With Enhanced Low‐Density Lipoprotein Cholesterol Lowering With Bempedoic Acid

    Factors Associated With Enhanced Low‐Density Lipoprotein Cholesterol Lowering With Bempedoic Acid by Christie M. Ballantyne, Harold E. Bays, Michael J. Louie, Jeremy Smart, Yang Zhang, Kausik K. Ray

    Published 2022-08-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study

    Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study by Isabella Sudano, Stephan Krähenbühl, François Mach, Anne Anstett, Nafeesa Dhalwani, Ian Bridges, Mahendra Sibartie, Kausik K. Ray

    Published 2024-01-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study

    Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study by Ioanna Gouni-Berthold, Frank Schaper, Ulrike Schatz, Anja Tabbert-Zitzler, Uwe Fraass, Sarah Sauer, Kausik K. Ray

    Published 2022-12-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Time‐Dependent Cardiovascular Treatment Benefit Model for Lipid‐Lowering Therapies

    Time‐Dependent Cardiovascular Treatment Benefit Model for Lipid‐Lowering Therapies by Irfan Khan, Eric D. Peterson, Christopher P. Cannon, Lauren E. Sedita, Jay M. Edelberg, Kausik K. Ray

    Published 2020-08-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations

    Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations by Carl E. Orringer, Lale Tokgozoglu, Kevin C. Maki, Kausik K. Ray, Joseph J. Saseen, Alberico L. Catapano

    Published 2020-11-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?

    Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association? by Anastasios Makris, Fotios Barkas, Petros P. Sfikakis, Evangelos Liberopoulos, Theodosios D. Filippatos, Kausik K. Ray, Aris P. Agouridis

    Published 2023-12-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease

    Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease by Laura H. Gunn, Ailsa J. McKay, Amy Feng, Michael J. Louie, Christie M. Ballantyne, Kausik K. Ray

    Published 2022-08-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Overview of a collaborative global effort to address the burden of familial hypercholesterolaemia

    Overview of a collaborative global effort to address the burden of familial hypercholesterolaemia by Alexander R.M. Lyons, Christophe A.T. Stevens, Kanika I. Dharmayat, Dr Antonio J. Vallejo-Vaz, Kausik K. Ray

    Published 2024-03-01
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis

    Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis by Ramyashree Tummala, Manasvi Gupta, Arvind Reddy Devanabanda, Dhrubajyoti Bandyopadhyay, Wilbert S. Aronow, Kausik K. Ray, Mamas Mamas, Raktim K. Ghosh

    Published 2022-12-01
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI studyResearch in context

    Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA... by Julia Brandts, Sarah Bray, Guillermo Villa, Alberico L. Catapano, Neil R. Poulter, Antonio J. Vallejo-Vaz, Kausik K. Ray

    Published 2023-08-01
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    Ensemble machine learning methods in screening electronic health records: A scoping review

    Ensemble machine learning methods in screening electronic health records: A scoping review by Christophe AT Stevens, Alexander RM Lyons, Kanika I Dharmayat, Alireza Mahani, Kausik K Ray, Antonio J Vallejo-Vaz, Mansour TA Sharabiani

    Published 2023-05-01
    Get full text
    Article
    Save to List
    Saved in:
  14. 14
    FH ALERT: efficacy of a novel approach to identify patients with familial hypercholesterolemia

    FH ALERT: efficacy of a novel approach to identify patients with familial hypercholesterolemia by Felix Fath, Andreas Bengeser, Mathias Barresi, Priska Binner, Stefanie Schwab, Kausik K. Ray, Bernhard K. Krämer, Uwe Fraass, Winfried März

    Published 2021-10-01
    Get full text
    Article
    Save to List
    Saved in:
  15. 15
    Lipid lowering with inclisiran: a real-world single-centre experience

    Lipid lowering with inclisiran: a real-world single-centre experience by Jaimini Cegla, Ben Jones, Kausik K Ray, Stewart Wilson, Ferruccio De Lorenzo, Pritpal Padam, Lucy Barton, Alessia David, Shahenaz Walji

    Published 2022-12-01
    Get full text
    Article
    Save to List
    Saved in:
  16. 16
    Premature morbidity and mortality associated with potentially undiagnosed familial hypercholesterolemia in the general population

    Premature morbidity and mortality associated with potentially undiagnosed familial hypercholesterolemia in the general population by Kausik K. Ray, Demetris Pillas, Savvas Hadjiphilippou, Kamlesh Khunti, Sreenivasa Rao Kondapally Seshasai, Antonio J. Vallejo-Vaz, David Neasham, Janet Addison

    Published 2023-09-01
    Get full text
    Article
    Save to List
    Saved in:
  17. 17
    Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11

    Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11 by Wolfgang Koenig, Kausik K. Ray, Ulf Landmesser, Lawrence A. Leiter, Gregory G. Schwartz, R. Scott Wright, Lorena Garcia Conde, Jackie Han, Frederick J. Raal

    Published 2023-06-01
    Get full text
    Article
    Save to List
    Saved in:
  18. 18
    Improving the Detection of Potential Cases of Familial Hypercholesterolemia: Could Machine Learning Be Part of the Solution?

    Improving the Detection of Potential Cases of Familial Hypercholesterolemia: Could Machine Learning Be Part of the Solution? by Christophe A. T. Stevens, Antonio J. Vallejo‐Vaz, Joana R. Chora, Fotis Barkas, Julia Brandts, Alireza Mahani, Leila Abar, Mansour T. A. Sharabiani, Kausik K. Ray

    Published 2024-06-01
    Get full text
    Article
    Save to List
    Saved in:
  19. 19
    Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials

    Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials by Antonio J. Vallejo‐Vaz, Henry N. Ginsberg, Michael H. Davidson, Robert H. Eckel, Christopher P. Cannon, L. Veronica Lee, Laurence Bessac, Robert Pordy, Alexia Letierce, Kausik K. Ray

    Published 2018-09-01
    Get full text
    Article
    Save to List
    Saved in:
  20. 20
    Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol

    Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol by Helen M. Colhoun, Lawrence A. Leiter, Dirk Müller-Wieland, Bertrand Cariou, Kausik K. Ray, Francisco J. Tinahones, Catherine Domenger, Alexia Letierce, Marc Israel, Rita Samuel, Stefano Del Prato

    Published 2020-02-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: